Ellen Holm Nielsen

Corporate Officer/Principal at University of Southern Denmark

Consumer Services

Health Technology

Profile

Ellen Holm Nielsen is currently a Principal at the University of California, Berkeley, the University of Copenhagen, the University of Southern Denmark, and Albert Einstein College of Medicine, Inc. She previously worked as a Director at Profylakse ApS.

Ellen Holm Nielsen active positions

Companies	Position	Start
University of Southern Denmark	Corporate Officer/Principal	-
University of California, Berkeley	Corporate Officer/Principal	-
Albert Einstein College of Medicine, Inc.	Corporate Officer/Principal	2009-08-13
University of Copenhagen	Corporate Officer/Principal	-

All active positions of Ellen Holm Nielsen

Former positions of Ellen Holm Nielsen

Companies	Position	End
Profylakse ApS Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations.	Director/Board Member	2013-11-21

See the detail of Ellen Holm Nielsen's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ellen Holm Nielsen's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Profylakse ApS Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations.	Health Technology